Krystal Biotech (KRYS) Accumulated Expenses (2016 - 2026)

Krystal Biotech has reported Accumulated Expenses for 11 years, with the latest figure at $35.6 million in Q2 2026.

• Accumulated Expenses for Q2 2026 came in at $35.6 million, up 34.12% year-over-year; the trailing twelve-month figure through Jun 2026 was $35.6 million (up 34.12% YoY), and the FY2025 annual result was $39.8 million, down 32.61% from the prior year.
• Accumulated Expenses rose to $35.6 million in Q2 2026, from $31.2 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $59.0 million in Q4 2024 and troughed at $17.9 million in Q2 2023.
• A 5-year average of $32.6 million and a median of $29.5 million in 2023 frame the typical range for Accumulated Expenses.
• The widest annual swing landed in 2022, when Accumulated Expenses surged 663.94%; it then sank 42.12% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $23.3 million in 2022, then dropped by 7.7% to $21.5 million in 2023, then soared by 174.23% to $59.0 million in 2024, then tumbled by 32.61% to $39.8 million in 2025, then dropped by 10.53% to $35.6 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $35.6 million in Q2 2026, $31.2 million in Q1 2026, and $39.8 million in Q4 2025.